(Q36351941)

13 August 2017

1 reference

title

Müllerian inhibiting substance in reproduction and cancer (English)

1 reference

13 August 2017

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

19 October 2022

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

19 October 2022

author name string

Donahoe PK

1

1 reference

13 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1637555

19 October 2022

publication date

1 June 1992

1 reference

full work available at URL

13 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fmrd.1080320213

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

https://onlinelibrary.wiley.com/doi/full/10.1002/mrd.1080320213

19 October 2022

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Molecular Reproduction and Development

19 October 2022

published in

1 reference

13 August 2017

volume

32

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

168-172

1 reference

Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FMRD.1080320213

Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMRD.1080320213

Recombinant human müllerian inhibiting substance inhibits epidermal growth factor receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMRD.1080320213

Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMRD.1080320213

Isolation of the rat gene for Mullerian inhibiting substance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMRD.1080320213

Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMRD.1080320213

Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMRD.1080320213

Complementary DNA sequences of ovarian follicular fluid inhibin show precursor structure and homology with transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMRD.1080320213

Expression cloning of an activin receptor, a predicted transmembrane serine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMRD.1080320213

Delay of testicular differentiation in the B6.YDOM ovotestis demonstrated by immunocytochemical staining for Müllerian inhibiting substance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMRD.1080320213

Expression cloning and characterization of the TGF-beta type III receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMRD.1080320213

A maternal mRNA localized to the vegetal hemisphere in Xenopus eggs codes for a growth factor related to TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMRD.1080320213

Importance of FSH-releasing protein and inhibin in erythrodifferentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMRD.1080320213

Mullerian inhibiting substance binding and uptake

21 January 2018

5

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Müllerian inhibiting substance depresses accumulation in vitro of disaturated phosphatidylcholine in fetal rat lung

19 October 2022

6

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Sex-specific fetal lung development and müllerian inhibiting substance

19 October 2022

7

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo

19 October 2022

8

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Mullerian inhibiting substance inhibits growth of a human ovarian cancer in nude mice

19 October 2022

11

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Rapid growth of human cancer cells in a mouse model with fibrin clot subrenal capsule assay

19 October 2022

13

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Müllerian inhibiting substance inhibition of a human endometrial carcinoma cell line xenografted in nude mice

19 October 2022

14

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line

19 October 2022

15

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Müllerian Inhibiting Substance as a Marker for Ovarian Sex-Cord Tumor

19 October 2022

16

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

An immunoassay to detect human müllerian inhibiting substance in males and females during normal development

19 October 2022

18

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

The hormonal control of testicular descent

19 October 2022

19

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Mullerian inhibiting substance ontogeny and its modulation by follicle-stimulating hormone in the rat testes

19 October 2022

21

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Müllerian inhibiting substance production and cleavage is modulated by gonadotropins and steroids

19 October 2022

22

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Mullerian duct regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domain

19 October 2022

26

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Identification of müllerian inhibiting substance specific binding in human cell lines

19 October 2022

27

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Human müllerian inhibiting substance: enhanced purification imparts biochemical stability and restores antiproliferative effects

19 October 2022

32

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure

19 October 2022

33

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

The ontogeny of mullerian inhibiting substance in granulosa cells of the bovine ovarian follicle

19 October 2022

34

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Müllerian inhibiting substance as oocyte meiosis inhibitor

19 October 2022

35

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Mullerian inhibiting substance in the adult rat ovary during various stages of the estrous cycle

19 October 2022

37

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Human recombinant mullerian inhibiting substance inhibition of rat oocyte meiosis is reversed by epidermal growth factor in vitro

19 October 2022

38

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Anti-Müllerian hormone produces endocrine sex reversal of fetal ovaries

19 October 2022

39

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

Novel regulators of bone formation: molecular clones and activities

19 October 2022

44

1 reference

https://api.crossref.org/works/10.1002/MRD.1080320213

19 October 2022

Identifiers

1 reference

13 August 2017

1 reference